The NCL antagonists HB-19 and its analog N6L are able to impair tumor growth and tumor angiogenesis, to inhibit tumor progression and metastasization and to promote the normalization of tumor vasculature, features reported also after the administration of the anti-NCL antibody NCL3 [21, 33–35]. The gene discussed is CAPN5; the disease is neoplasm.